ERBB2 and breast carcinoma: Overexpression/amplification of HER2 (ERBB2) is used to predict the response to monoclonal antibodies such as trastuzumab and pertuzumab in breast cancer [65] and the response to trastuzumab in esophago-gastric adenocarcinoma [66].